Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Hypertension
Interstitial Lung Disease

Interventions

DRUG: Treprostinil Palmitil Inhalation Powder
DRUG: Placebo

Sponsor

Insmed Incorporated